A5070251398- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- Liver physiology and pathology
- Pancreatitis Pathology and Treatment
- Catalytic Processes in Materials Science
- PARP inhibition in cancer therapy
- Synthesis of Indole Derivatives
- Nigella sativa pharmacological applications
- Mass Spectrometry Techniques and Applications
- Animal Behavior and Welfare Studies
- Electron Spin Resonance Studies
- Neuroendocrine regulation and behavior
- Prostate Cancer Treatment and Research
- Synthesis and Biological Evaluation
- Catalysis and Oxidation Reactions
- Stress Responses and Cortisol
- Catalysts for Methane Reforming
Stanford University
2025
University of Rochester Medical Center
2020
University of California, Berkeley
2019
University of California, Riverside
2013-2015
CO2 reduction by H2 on heterogeneous catalysts is an important class of reactions that has been studied for decades. However, atomic scale details structure-function relationships are still poorly understood. Particularly, it suggested metal particle size plays a unique role in controlling the stability hydrogenation and distribution active sites, which dictates reactivity selectivity. These studies often have not considered possible isolated sites observed dependences. Here, we utilize...
After failing primary and secondary hormonal therapy, castration-resistant neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in PCa potentially synergizing inhibiting metastasis growth are urgently needed. Phosphorylated (activated) AXL expression human metastases was assessed by immunohistochemical staining. We evaluated effects of...
Soybean lipoxygenase (SLO) has served as a prototype for understanding the molecular origin of enzymatic rate accelerations. The double mutant (DM) L546A/L754A is considered dramatic outlier, due to unprecedented size and near temperature-independence its primary kinetic isotope effect, low catalytic efficiency, elevated enthalpy activation. To uncover physical basis these features, we herein apply three structural probes: hydrogen–deuterium exchange mass spectrometry, room-temperature X-ray...
<p>Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or combination increased (BMD) the tibiae to a similar extent determined by microCT.</p>
<p>Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls intratibial LuCaP 147CR PDX model while total AKT proteins were similar. Scale bar = 10 μm.</p>
<p>Figure S5. Mouse body weight change (%) after treatment for 30 days. None of the groups displayed significant differences in weight, indicating overall low toxicity from batiraxcept and docetaxel at doses administered.</p>
<p>Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse detected by ELISA.</p>
<p>Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences among groups detected by ELISA</p>
<div>AbstractPurpose:<p>After failing primary and secondary hormonal therapy, castration-resistant neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in potentially synergizing inhibiting metastasis growth are urgently needed.</p>Experimental Design:<p>Phosphorylated (activated) AXL expression human metastases...
<p>Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth metastasis LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining Ku70 IHC cells the tibiae 147 (A), 35 (B). Human PCa marked by were decreased after 30 days treatment intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, (10 mg/kg/QW, 9) compared to vehicle controls (n 8,10). C-D, Quantification Ku70-positive areas mouse tibia specimens...
Abstract The FDA-approved anti-androgen Enzalutamide (Enz) has been used successfully as the last line therapy to extend castration-resistant prostate cancer (CRPC) patients’ survival by an extra 4.8 months. However, CRPC patients eventually develop Enz-resistance that may involve induction of androgen receptor (AR) splicing variant ARv7. Here we found Cisplatin (Cis) or Carboplatin, currently in chemotherapy/radiation suppress tumor progression, could restore Enz sensitivity multiple...